Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06064071 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 22, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Primary endpoint revised
    • Interventions: Meibomian Gland Expression (MGX) (Procedure), Nordlys SWT IPL (Device) to Meibomian Gland Expression (MGX) (Procedure), Nordlys SWT IPL (Device), Sham Nordlys SWT IPL (Device)
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints revised (2)
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).
Trial Details
NCT Number NCT06064071
Lead Sponsor Candela Corporation
Conditions
(from sponsor)		 Meibomian Gland Dysfunction, Dry Eye Disease
Related terms Dry Eye Syndromes, Meibomian Gland Dysfunction
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov